NEW YORK--(BUSINESS WIRE)--Pragma Pharmaceuticals is pleased to announce that it has finalized the acquisition of the Keflex product line from Shionogi Inc.
Pragma is working toward launching later this month with Fera Pharmaceuticals managing the sales and marketing of the product.
Keflex is the gold standard in the cephalosporin class of antibiotics. Cephalexin is among the most widely used anti-infectives in the US, with over 22 million prescriptions dispensed annually.
About Keflex
Keflex (cephalexin capsules, USP) is a first-generation cephalosporin antibiotic shown to be active against strains of both gram-positive and gram-negative aerobes in vitro and in clinical infections. Keflex is indicated for treatment of the following infections: respiratory tract infections, otitis media, skin and skin structure infections, bone infections, and genitourinary tract infections. More information on Keflex and full prescribing information are available at www.ferapharma.com.
Pragma Pharmaceuticals
Louis B. DellaFera, Pharm. D., 516-277-1450
Louis@pragmapharma.com
